A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of IPI-504 in Patients With Metastatic and/or Unresectable GIST Following Failure of at Least Imatinib and Sunitinib

Trial Profile

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of IPI-504 in Patients With Metastatic and/or Unresectable GIST Following Failure of at Least Imatinib and Sunitinib

Discontinued
Phase of Trial: Phase III

Latest Information Update: 27 Oct 2014

At a glance

  • Drugs Retaspimycin (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Registrational; Therapeutic Use
  • Acronyms RING
  • Sponsors Infinity Pharmaceuticals
  • Most Recent Events

    • 21 Apr 2012 Additional trial locations added as reported by European Clinical Trials Database.
    • 21 Apr 2012 Planned number of patients changed from 195 to 229 as reported by European Clinical Trials Database.
    • 24 Jan 2010 Tolerability results presented at the 2010 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top